# Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/lurbinectedin-as-second-line-treatment-for-patients-with-small-cell-lung-cancer/

## Facts

| Field | Value |
| --- | --- |
| Author Names | José Trigo,Vivek Subbiah,Benjamin Besse,Víctor Moreno,Rafael López‐López,María Ángeles Sala,Solange Peters,Santiago Ponce,Cristian Fernández,Vicente Alfaro,Javier Gómez,Carmen Kahatt,Ali Zeaiter,Khalil Zaman,Valentina Boni,Jennifer Arrondeau,Maite Martínez,Jean‐Pierre Delord,Ahmad Awada,Rebecca Kristeleit,M.E. Olmedo,Luciano Wannesson,Javier Valdivia,María Jesús Rubio,Antonio Antón,John Sarantopoulos,Sant P. Chawla,Joaquín Mosquera,M. D’Arcangelo,Armando Santoro,Víctor M. Villalobos,Jacob Sands,Luis Paz‐Ares |
| Citations | 476 |
| DOI | 10.1016/s1470-2045(20)30068-1 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3013383466 |
| PMID | 32224306 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Benjamin Besse](https://scholariq.org/researchers/benjamin-besse/)
- [Rebecca Kristeleit](https://scholariq.org/researchers/rebecca-kristeleit/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

## Paper topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.